title: Evidence-based treatment and prevention of external genital warts in female pediatric and adolescent patients.
abstract: External anogenital warts, or condylomata acuminata, are caused by the proliferation of squamous epithelial cells secondary to human papillomavirus infection. In sexually active adults and adolescents, anogenital warts are a common sexually transmitted disease, but in children they may be a sign of sexual abuse. There are several treatment options available for anogenital warts, but no treatment has been proven to be the most efficacious, and recurrence after clinical clearance is common. Evidence-based treatment of genital warts is challenging because of the lack of controlled trials comparing treatments, especially in pediatric and adolescent populations. This paper discusses various treatment modalities such as physical destruction, cytotoxic agents, and immunomodulating therapies. Many variables influence the selection of a treatment, such as the size, quantity, and location of the warts; and the patient and provider preference, and its availability and cost. All treatments can cause local side effects, and patient tolerability must also be factored into treatment selection. Many treatments have similar clearance and recurrence rates, and none of the treatments completely eliminates the virus. With the numerous challenges surrounding the treatment of anogenital warts, the primary prevention of HPV infection through vaccination is a key component in decreasing the incidence of the disease.
authors.affiliation: University of Pittsburgh Department of Dermatology, Pittsburgh, PA 15213, USA.
authors.forename: L
authors.initials: L
authors.lastname: Thornsberry
authors.forename: J C
authors.initials: JC
authors.lastname: English
mesh_terms: D000293:Adolescent; D002648:Child; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000628:therapy*; D003452:Cryosurgery; D003603:Cytotoxins / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D054025:Lasers, Dye / Q000627:therapeutic use; D054020:Lasers, Gas / Q000627:therapeutic use; D053918:Papillomavirus Vaccines; D012008:Recurrence
chemical_list: D003603:Cytotoxins; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D007155:Immunologic Factors; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18